Analysts Hail Pearson's Return To Valeant As Patent Challenges From Allergan Looms – ValueWalk Premium
Valeant 2 29 stock price

Analysts Hail Pearson's Return To Valeant As Patent Challenges From Allergan Looms

Patent challenges, restatement of earnings and lack of forward looking guidance are all greeting Michael Pearson, Valeant's former Chairman and CEO, who is coming back to the firm today. Pearson's job responsibilities are being clipped, with his chairman title being an oversight role at Valeant to be executed by Robert A. Ingram, a former executive of GlasxoSmithKline, the company announced over the weekend.


Analysts encouraging on Pearson's . . .

SORRY!

This content is exclusively for paying members.

If you are subscribed and having an account error please clear cache and cookies if that does not work email support@valuewalk.com or click Chat.


X
Saved Articles
X
TextTExtLInkTextTExtLInk
Here’s a Tip: Read What Professional Investors Read

ValueWalk Premium is for investors looking to improve their investment process AND keep up-to-date on the latest industry trends.

It’s THE resource for value investing and hedge funds.   

And with a free three-day trial and $29.99 per month thereafter, it’s a value in its own right.

SIGN UP NOW
0